The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas

Cancer

Volumn 106, Issue 10, 2006, Pages 2119-2127

  Brücher, Björn L D M ^a   Becker, Karen ^b   Lordick, Florian ^a   Fink, Ulrich ^a   Sarbia, Mario ^b   Stein, Hubert ^a   Busch, Raymonde ^b   Zimmermann, Frank ^b   Molls, Michael ^b   Höfler, Heinz ^b   Siewert, Jörg R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Esophageal carcinoma; Histopathology; Multimodal therapy; Neoadjuvant radiochemotherapy; Response

Indexed keywords

CISPLATIN; FLUOROURACIL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLASSIFICATION; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG DISEASE; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL INVASION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

AGED; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; EVALUATION STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33646379877     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21850     Document Type: Article

References (50)

1. Lehnert T. Multimodal therapy for squamous carcinoma of the oesophagus. Br J Surg. 1999;86:727-739.
2. Brücher BLDM, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer. 2001;92:2228-2233.
3. Brücher BLDM, Stein HJ, Zimmermann F, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective Phase-II trial. Eur J Surg Oncol. 2004;30:963-971.
4. Kelsen D. Preoperative chemoradiotherapy for esophageal cancer. J Clin Oncol. 2001;19:283-285.
5. Kitajima M, Kitagawa Y. Surgical treatment of esophageal cancer-the advent of the era of individualization. N Engl J Med. 2002;347:1705-1709.
6. Siewert JR, Stein HJ, Feith M, Brücher BLDM, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234:360-367; discussion, 368-369.
7. Stein HJ, Sendler A, Fink U, Siewert JR. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am. 2000;80:659-682; discussion, 683-686.
8. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-2174.
9. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial [see comments]. J Thorac Cardiovasc Surg. 1997;114:210-217.
10. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
11. Burmeister BH. A randomized Phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus [abstract]. Proc Am Soc Clin Oncol. 2002;21:130.
12. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
13. Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer, 2004;100:2347-2354.
14. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
15. Wieder HA, Brücher BLDM, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
16. Brücher BLDM, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300-309.
17. Flamen P, Lerut T, Haustermans K, Van Cutsem E, Mortelmans L. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging. 2004;48:96-108.
18. Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;184:279-283.
19. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-1160; discussion, 1152-1160.
20. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21:19-22.
21. Greene FL. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol. 2003;21:23-29.
22. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530.
23. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686.
24. Fink U, Stein HJ, Siewert JR. [Multimodal therapy of tumors of the upper gastrointestinal tract]. Chirurg. 1998;69:349-359.
25. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-1984.
26. Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg. 2004;240:791-800.
27. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73:1779-1784.
28. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16:1104-1109; discussion, 1110.
29. Raoul JL, Le Prise E, Meunier B, Heresbach D, Campion JP, Launois B. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1998;42:29-34.
30. Schlag P. [Randomized study of preoperative chemotherapy in squamous cell cancer of the esophagus. CAO Esophageal Cancer Study Group]. Chirurg. 1992;63:709-714.
31. Gibson MK, Forastiere AA. Combined-modality therapy for esophageal cancer: are we making progress? Cancer J. 2003;9:238-240.
32. Bartels H, Stein HJ, Siewert JR. Risk analysis in esophageal surgery. Recent Results Cancer Res. 2000;155:89-96.
33. Siewert JR, Holscher AH, Roder JD, Bartels H. En-bloc esophagectomy in esophageal cancer. Langenbecks Arch Chir. 1998;373:367-376.
34. Steinau HU, Biemer E, Bader M, Holscher M, Siewert JR. Reconstruction of the Cervical Esophagus by Microsurgical Transfer of Intestinal Segment. New York: Springer; 1988.
35. Brücher BLDM, Specht K, Stein H, Molls M, Siewert JR, Hofler H. Cyclin D1 as a predictive marker in patients with esophageal squamous cell carcinoma and neoadjuvant radiochemotherapy [abstract]. Proc Am Soc Clin Oncol. 2003;22:289.
36. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol. 1995;48:1495-1501.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;75:457-487.
38. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
39. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:1987-2001.
40. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
41. Fang W, Kato H, Tachimori Y, Igaki H, Sato H, Daiko H. Analysis of pulmonary complications after three-field lymph node dissection for esophageal cancer. Ann Thorac Surg. 2003;76:903-908.
42. Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE. Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002;73:922-926.
43. Dimick JB, Pronovost PJ, Cowan JA, Lipsett PA. Surgical volume and quality of care for esophageal resection: do high-volume hospitals have fewer complications? Ann Thorac Surg. 2003;75:337-341.
44. Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol. 2000;18:455-462.
45. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC 3rd, Pairolero PC. Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus. Ann Thorac Surg. 2004;77:1193-1198; discussion, 1198-1199.
46. Siewert JR, Brücher BLDM, Stein HJ, Fink U. [Esophagus carcinoma-systemic or local risk of recurrence-which perioperative measures are successful?] Langenbecks Arch Chir Suppl Kongressbd. 1998;115:290-294.
47. Adelstein DJ, Rice TW, Becker M, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 1997;80:1011-1020.
48. Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004;60:427-436.
49. Araujo CM, Souhami L, Gil RA, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer. 1991;67:2258-2261.
50. Wobbes T, Baron B, Paillot B, et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. Eur J Cancer. 2001;37:470-477.